MedPath

Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy

Phase 2
Conditions
Ovarian Endometrioma
Registration Number
NCT01596985
Lead Sponsor
Plasma Surgical Inc
Brief Summary

Objective: To compare loss of ovarian parenchyma following ovarian endometrioma ablation using the PlasmaJet system versus cystectomy, using postoperative examination by 3D ultrasound.

Design: Prospective comparative study. Setting: Two experienced surgeons practicing in two University tertiary referral centers.

Patients: Fifty women with no previous history of ovarian surgery managed for unilateral ovarian endometrioma \> 30 mm in diameter.

Interventions: Endometrioma ablation by plasma energy using the PlasmaJet system and ovarian tissue sparing cystectomy.

Main Outcome Measures: 3D ultrasound assessment of postoperative reduction in ovarian volume and antral follicle count (AFC) .

Detailed Description

The management of ovarian endometriomas in women wishing to conceive remains challenging. Recent data suggest that excising endometriomas by ovarian tissue sparing cystectomy does not avoid inadvertent removal of ovarian parenchyma surrounding the cyst, particularly in enlarged cysts. Although several authors question whether the ovarian parenchyma immediately surrounding the cyst may still be functional, there is little doubt that postoperative fertility could be significantly impaired by loss of ovarian cortex and provokes the question as to whether pregnancy should be initiated before performing a cystectomy, whenever this scenario is possible. However ovarian surgery cannot always be delayed to the postpartum period, numerous women require endometrioma management while not seeking an immediate pregnancy and still wish to conserve their procreative capabilities.

After a period of some years during which cystectomy appeared to be the best surgical technique in the treatment of ovarian endometriomas in women wishing to become pregnant, recent data have suggested that ablation of the inner layer of the endometrioma may be a valuable alternative technique, as long as the energy employed avoids thermal diffusion to surrounding ovarian tissue. The Department of Gynecology at the University Hospital in Rouen, France have introduced ablation by plasma energy using the PlasmaJet system (Plasma Surgical Ltd, Abingdon, UK) and have already been able to report encouraging results based on non comparative pilot studies and on retrospective "before and after" comparative study.

The aim of the study is to prospectively compare loss of ovarian parenchyma and decrease in antral follicle count (AFC) following ovarian endometrioma ablation using plasma energy versus cystectomy, when performed by only two expert surgeons. Postoperative examination is carried out by 3D ultrasound.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • Age between 18 and 45 years;
  • Surgery required by pelvic pain or infertility related to endometriosis;
  • Clinical and imaging data proving unilateral ovarian endometrioma which diameter exceeds 30 mm.
Exclusion Criteria
  • Previous surgery on ovaries or IVF procedures;
  • Bilateral endometriomas;
  • Pregnancy
  • Woman not French speaker.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Loss of ovarian volume3 months postoperatively

Evaluation of ovarian volumes of both the operated and the contralateral healthy ovary using a tridimensional ultrasound by vaginal route. The volume of each ovary expressed in cm³ was estimated using the formula D1 x D2 x D3 x π / 6. The Mann and Whitney test is performed to compare measurements made on the operated ovaries vs. those made on the contralateral ovaries.

Secondary Outcome Measures
NameTimeMethod
Decrease in ovarian antral follicles count (AFC)3 months postoperatively

Evaluation of antral follicle counts in both the operated and the contralateral, healthy ovary, using tridimensional ultrasound. The Mann and Whitney test is performed to compare the decrease in AFC depending on surgical procedure.

Antimullerian Hormone level (AMH)3 months postoperatively

AMH level are measured before and 3 months after the surgery to evaluate the decrease in AMH level depending on surgical technique.

Trial Locations

Locations (1)

University Hospital

🇫🇷

Rouen, Seine-Maritime, France

University Hospital
🇫🇷Rouen, Seine-Maritime, France
Michel Canis, MD PhD
Contact
+33473750750
mcanis@chu-clermontferrand.fr
Michel Canis, MD
Principal Investigator
Jean-Luc Pouly, MD
Sub Investigator
Nicolas Bourdel, MD
Sub Investigator
Horace Roman, MD PhD
Contact
+33232888643
horace.roman@gmail.com
Horace Roman, MD, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.